Skip to main content
OpenTrials
Completed

NCT Number: NCT00414596

Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System

This pilot study will evaluate the effectiveness and safety of the Axiom Worldwide DRX9000 for active treatment of chronic low back pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Low Back Pain Back Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Vibrance Medical Group, Beverly Hills, California, United States

Loading trial locations.

About this study

Currently, there are no prospective safety and/or outcomes studies utilizing the DRX9000™ in the peer-reviewed medical literature. There are published trials utilizing similar machines which provided evidence in support of the FDA granted indications for use spinal decompression and of the DRX9000™. Axiom Worldwide has determined it will be of benefit to the continuing medical care of patients and a furthering of the scientific knowledge of the treatment of LBP to complete such a prospective evaluation using a standardized treatment protocol. This study will therefore attempt to establish and validate the safety and efficacy of this computerized spinal decompression system in the treatment of LBP and sciatica.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, greater than 18 years of age
  • Able to understand possible risks and benefits and provide written informed consent (ICF) to the IRB approved clinical multimodal protocol
  • LBP with an intensity level of greater than 4 on an eleven point numerical pain rating scale (VRS) of 0-10 (with 0 - no pain and 10 - worst possible pain)
  • Completed the necessary diagnostic and medical history evaluations as described in the protocol to confirm the patient's diagnosis and eligibility for the study and DRX9000 treatment protocol.
  • Willing and able to complete a six week 20 session of DRX9000 outpatient treatments and a minimum of 6 months follow-up

Exclusion criteria

  • Pregnancy
  • Evidence of neurological motor deficits on clinical examination
  • Evidence of spinal cord compression, metastatic cancer, tumor, hematoma, infection or compression fracture
  • Evidence of severe central stenosis with neurological deficits or nerve root entrapment
  • Litigation for health-related claim (in process or pending), Worker's Compensation, or Personal Injury
  • Previous spine fusion surgery, insertion of hardware or artificial disc
  • Hemiplegia or paraplegia
  • History of severe cardiovascular or metabolic disease, or abdominal aortic aneurysm
  • Unwillingness to postpone other types of therapy for LBP during the 6 week treatment sessions
  • Known alcohol abuse or drug abuse
  • Height less than 4 feet 10 inches (147 cm) or greater than 6 feet 8 inches (203 cm)
  • Body weight greater than 300 pounds (136 kg)

Treatment and study plan

DRX9000™

Device

Device is designed to apply spinal decompressive forces.

Primary outcomes

  1. Post-treatment Numerical Pain Intensity Rating Scale (VRS), Which is a Scale From 0-10 (0=no Pain, 10= Worst Pain)

    Time frame: Six weeks

    The numerical results of the post-treatment verbal numerical pain intensity rating scale (VRS) following completion of a standard six week series of 20 DRX9000 treatments.

Secondary outcomes

  1. Recurrence for Significant (VRS Greater Than or Equal to 4) LBP Following Completion of 6 Weeks of DRX9000 Treatment.

    Time frame: Six weeks

    The number of Subjects reporting VRS greater than or equal to 4 for LBP following completion of 6 weeks of DRX9000 treatment will be recorded.

  2. Change in Functional Capacity From Baseline to Six Weeks (The Revised Oswestry Pain Questionaire)

    Time frame: Six weeks

    Subject functional capacity following 6 weeks of DRX9000 treatment will be measured as a numerical score by the Revised Oswestry Pain Questionaire (scale 0-50, 0=pain without effects). Functional capacity was assessed at Baseline, 3 Weeks and 6 Weeks.

  3. Patient's Satisfaction With Treatment Procedures Following 6 Weeks of DRX9000 Treatment.

    Time frame: Six weeks

    Patient's satisfaction with treatment procedures following 6 weeks of DRX9000 treatment was measured on a scale from 0-10 (0= very unsatisfied, 10=very satisfied).

  4. Number of Adverse Events Following 6 Weeks of DRX9000 Treatment.

    Time frame: Six weeks

    Total number of adverse events reported following 6 weeks of DRX9000 treatment.

  5. Number of Patients Who Withdraw From Study.

    Time frame: 6 weeks

    Total number of patients who withdrew during the 6 weeks of treatment.

Sponsors and collaborators

Lead sponsor

NEMA Research, Inc.

Industry

Registry information

Official study title

Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System For Treatment of Low Back Pain

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Dec 21, 2006
Registry last updated
Jun 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.